{"paper_id":"f0bfa250-62b3-4375-80dc-75fd7b5592b7","body_text":"Not satisfied with having a go with one or few mature oocytes in the business of baby making, controlled ovarian stimulation, or COS as we know it, has withstood the test of time for nearly four decades now. The many iterations of COS that have been witness to strategic upgrades at approximately 10-year intervals, over the years of clinical ARTs, took aim at essentially one objective: to obtain as many mature oocytes as possible for making, and cryopreserving, as many embryos as possible for our patients. The sine qua non that more is better has never held more importance to a discipline in human medicine than what we can fairly attribute to the practice of COS!\nAs with all medical treatments, taking along some risks, alongside intended benefits, comes with procedures whereby any number of conditions, iatrogenic or patient-specific, can lead to unwanted side effects. Hence, the matter of ovarian hyperstimulation syndrome (OHSS) was recognized early in the history of human ARTs as a potentially serious complication of COS.\nWith the quest for as many mature oocytes as possible being the modus operandi for COS, the immediate challenge has always been to rescue subsets of ovarian follicles destined to an atretic fate. The prize at hand being developmentally competent oocytes with physician oversight to minimize the incidence of OHSS. Managing OHSS risks among an ever-diversifying patient population has evolved in parallel to a collection of COS strategies from the days of native gonadotropin preparations to the recombinant products of the 1990s, to the more contemporary and combinatorial protocols invoking the utility of gonadotropins and GnRH agonists or antagonists. A quick look beyond triggering strategies for achieving oocyte maturity reminds us that more is at stake here with respect to compromising functionality of the ovarian luteal compartment as well as, and not to be minimized, ovarian vasculature and the incipient effects on local inflammation. Orvieto and colleagues were among the first to elaborate on the pathophysiological consequences of COS with respect to what had already been known about the physiological role of inflammation in spontaneous ovulation [1].\nThat ovulation in mammals had been broadly recognized as an inflammatory event with short-term physiological consequences was well appreciated, even more so as the molecular and gene expression rudiments of this process were linked to innate immunity and the basis for fertility [2]. However, what was awaiting better mechanistic definition and clarity, especially in the context of COS, was an explanation for the complex interactions between fluid balance, capillary dysfunction, and the immune system. Add to this plausible perfect storm the fact that hCG itself, the trigger of triggers until recently, has been known to impose stress on the vascular system systemically and at the level of the ovary. And as pointed out by Huang and colleagues, the delicate balance between inflammation, vascular biology, and immune system responsiveness likely underlies other not uncommon ovarian pathologies [3].\nSo where does this effort to maximize oocyte availability fit when examining the future of human ARTs? In one sense, the various versions of triggering continue today to reduce the chances of OHSS in some cases for patient subpopulations that would have been at heightened risk [4]. And, as was entertained earlier this year in JARG’s coverage of clinical in vitro maturation (IVM), moving from no stimulation to mild and gentler forms of stimulation proffers an alternative to conventional COS, but at the expense of obtaining large numbers of oocytes [5]. So where do we go from here?\nFirst of all, that the problems inherent to COS are manifest well beyond whatever perturbations in vascular physiology attend an ongoing cycle and the chances of cycle cancellation must be more fully appreciated. To wit, Conrad and collaborators have demonstrated how COS and the absence of a physiological corpus luteum compromise the maternal vasculature in ways that affect a woman’s health over the course of a pregnancy and beyond [6, 7]. This work alone should give pause to an aspect of COS as now applied as part of the ART routine. Even some of the newer areas of reproductive medicine, such as oncofertility, are revealing nuances calling for a more introspective analysis at the level of clinical application (see letter in this issue, In reply to: Christ J, Herndon CN, Yu B. Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients. J Assist Reprod Genet. 2021;38:751–6. https://doi.org/10.1007/s10815-020-02051https://doi.org/10.1007/s10815-021-02305).\nReturning to the subject of pathophysiology, the paper by Hulde and colleagues is enlightening and provocative in identifying molecular and cellular determinants that should be evaluated in the general population of infertility patients and in those individuals presenting as high-risk candidates for OHSS (Effects of controlled ovarian stimulation on vascular barrier and endothelial glycocalyx: a pilot study https://doi.org/10.1007/s10815-021-02233).\nAnd finally, any and all discussions of the efficiency of human ARTs, given the central role played by COS, would be incomplete without mention of how cycle design and trigger modality impact the percentage of retrieved oocytes that have actually reached, and, we hope, maintained a fertilizable lifespan conducive to further development of any resulting zygotes. Two papers in this issue expand on this topic. As Gonullu and colleagues now report, among the factors that impact the number and proportion of mature oocytes available for embryo production, using less total gonadotropin and more gonadotropin daily resulted in more immaturity of the retrieved oocytes (Oocyte stimulation parameters influence the number and proportion of mature oocytes retrieved in assisted reproductive technology cycles https://doi.org/10.1007/s10815-021-02220). And, as is well appreciated within our field, what to do with the oocytes that are immature at the time of retrieval has typically followed a course of action most similar to a scavenger hunt. That is, not doing anything special but holding on to GV or M1 staged oocytes for an extended period of time prior to ICSI will often yield mature oocytes owing to the developmentally diverse population of follicles from which they were obtained. Mandelbaum and her team draw attention to the developmental capabilities to these “late-comers” following ICSI and note that some benefit may be derived for patients yielding lower numbers at retrieval or in older women (Developmental potential of immature human oocytes aspirated after controlled ovarian stimulation https://doi.org/10.1007/s10815-021-02253).\nTaken together, COS contributes significantly to human ARTs and stands to continue to contribute to our understanding of ovarian physiology and pathophysiology. As oversight continues in the best interests of our patients, we should continue to observe, and not overlook, what this and other procedures used in the everyday practice of ARTs teaches us about the basic biology of human reproduction.\nFootnotes\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nReferences\n- 1.Orvieto R. Controlled ovarian hyperstimulation–an inflammatory state. J Soc Gynecol Investig. 2004;11(7):424–426. doi: 10.1016/j.jsgi.2004.05.001. [DOI] [PubMed] [Google Scholar]\n- 2.Wisniewski HG, Vilcek J. Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3/TSG-14. Cytokine Growth Factor Rev. 2004;15(2–3):129–146. doi: 10.1016/j.cytogfr.2004.01.005. [DOI] [PubMed] [Google Scholar]\n- 3.Huang Y, Hu C, Ye H, Luo R, Fu X, Li X, et al. Inflamm-aging: a new mechanism affecting premature ovarian insufficiency. J Immunol Res. 2019;2019:8069898. doi: 10.1155/2019/8069898. [DOI] [PMC free article] [PubMed] [Google Scholar]\n- 4.Orvieto R. Triggering final follicular maturation-hCG, GnRH-agonist or both, when and to whom? J Assist Reprod Genet. 2016. [DOI] [PMC free article] [PubMed]\n- 5.Quaas AM. Triggering change in stimulation protocols: a matter of oocyte maturation and beyond. J Assist Reprod Genet. 2021;38(6):1285–1287. doi: 10.1007/s10815-021-02223-z. [DOI] [PMC free article] [PubMed] [Google Scholar]\n- 6.Conrad KP, Petersen JW, Chi YY, Zhai X, Li M, Chiu KH, et al. Maternal cardiovascular dysregulation during early pregnancy after in vitro fertilization cycles in the absence of a corpus luteum. Hypertension. 2019;74(3):705–715. doi: 10.1161/HYPERTENSIONAHA.119.13015. [DOI] [PMC free article] [PubMed] [Google Scholar]\n- 7.Conrad KP, Graham GM, Chi YY, Zhai X, Li M, Williams RS, et al. Potential influence of the corpus luteum on circulating reproductive and volume regulatory hormones, angiogenic and immunoregulatory factors in pregnant women. Am J Physiol Endocrinol Metab. 2019. [DOI] [PMC free article] [PubMed]","source_license":"CC0","license_restricted":false}